Table 3 Clinical trials targeting CTCs for cancer treatment
From: New insights into the correlations between circulating tumor cells and target organ metastasis
ClinicalTrials.gov ID | Drug | Effect | Tumor | Phase | Status |
|---|---|---|---|---|---|
NCT03928210 | Digoxin | Disrupt CTC clusters | Breast cancer | Early Phase 1 | Active |
NCT02552394 | J591 | A monoclonal antibody that recognizes and eliminates CTCs expressing PSMA | Prostate cancer | Phase 1 | Completed |
NCT02602938 | Aspirin | Significantly reduces the number of CTCs and prevents CTCs from undergoing EMT | Colorectal cancer and breast cancer | Phase 2 | Completed |
NCT00429182 | Carboplatin, Cyclophosphamide and Thiotepa | Use chemotherapy drugs to inhibit the growth and spread of CTCs | Breast cancer | Phase 2 | Completed |
NCT00263211 | Plavix and Aspirin | Inhibition of platelet function to affect CTCs | Breast cancer | Phase 2 | Terminated |
NCT01126879 | Genistein | May stop the growth of tumor cells by blocking some of the enzymes needed for cell growth | Prostate cancer | Phase 2 | Terminated |
